Ericsson and Brighter Pioneer IoT Solution for Diabetes Treatments
Ericsson and its partner, Brighter, commercially introduced Actiste, the world’s first complete IoT-health solution for monitoring and treating insulin-dependent diabetes. The solution is initially being introduced in United Arab Emirates where approximately 480.000 insulin-dependent people and could benefit from using Actiste.
Actiste brings together all required functions into a single connected device: blood sampling, blood glucose measurement and insulin injection. The device is delivered as part of a subscription service, designed to simplify patient’s everyday life and optimize and improve treatments. The total number of people living with diabetes in the UAE is currently 1.2 million of which approximately 480.000 are insulin-dependent and could benefit from Brighter’s Actiste service.
“By partnering with Ericsson, we are able to offer a truly seamless customer experience. No matter where in the world patients decide to go, their generated health and treatment data will always be securely stored and available to improve their treatments,” said Henrik Norström, CEO, Brighter.
“Our global partnership with Brighter has now reached a stage of real deliveries to the market, utilizing the global connectivity service based on our IoT Accelerator. The result is an enhanced healthcare industry in the UAE and wider GCC, and an improved quality of life for diabetes patients,” Fadi Pharaon, President of Ericsson Middle East and Africa, said.
The cellular-enabled Actiste devices are managed by Ericsson’s IoT Accelerator and securely connected by leading communications service providers to deliver a consistent level of service and a single dashboard. This provides Brighter with a unified view regardless of where those devices are deployed in the world.